What is HC Wainwright's Estimate for Metagenomi Q3 Earnings?

Key Points

• HC Wainwright has raised its Q3 2025 earnings per share estimate for Metagenomi to ($0.52), an improvement from the previous estimate of ($0.57), and maintains a "Buy" rating with a target price of $7.00.
• The consensus for Metagenomi's full-year earnings is projected at ($2.46) per share, with additional future earnings estimates indicating continued losses through fiscal 2026.
• Despite mixed analyst ratings, with some downgrading the stock, Metagenomi currently holds an average rating of "Buy" and a price target of $10.00 from analysts.

Metagenomi, Inc. (NASDAQ:MGX - Free Report) - HC Wainwright boosted their Q3 2025 earnings per share estimates for shares of Metagenomi in a report released on Tuesday, August 19th. HC Wainwright analyst M. Kapoor now anticipates that the company will earn ($0.52) per share for the quarter, up from their previous estimate of ($0.57). HC Wainwright currently has a "Buy" rating and a $7.00 target price on the stock. The consensus estimate for Metagenomi's current full-year earnings is ($2.46) per share. HC Wainwright also issued estimates for Metagenomi's Q4 2025 earnings at ($0.56) EPS, FY2025 earnings at ($2.29) EPS, Q1 2026 earnings at ($0.61) EPS, Q2 2026 earnings at ($0.64) EPS, Q3 2026 earnings at ($0.66) EPS, Q4 2026 earnings at ($0.69) EPS and FY2026 earnings at ($2.60) EPS.

A number of other equities research analysts have also issued reports on the stock. Wells Fargo & Company cut their target price on shares of Metagenomi from $16.00 to $12.00 and set an "overweight" rating on the stock in a research note on Thursday, August 14th. Chardan Capital cut their price objective on Metagenomi from $12.00 to $11.00 and set a "buy" rating on the stock in a research note on Friday, August 15th. Finally, Wall Street Zen downgraded Metagenomi from a "hold" rating to a "strong sell" rating in a report on Thursday, May 22nd. Three research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $10.00.

Metagenomi Price Performance

Shares of MGX stock opened at $1.85 on Thursday. The firm has a market cap of $69.43 million, a P/E ratio of -0.78 and a beta of -0.12. Metagenomi has a 1-year low of $1.23 and a 1-year high of $4.92. The firm has a fifty day moving average of $1.91 and a two-hundred day moving average of $1.84.

Metagenomi (NASDAQ:MGX - Get Free Report) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.54) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.68) by $0.14. Metagenomi had a negative net margin of 257.99% and a negative return on equity of 37.84%. The firm had revenue of $8.51 million for the quarter, compared to analysts' expectations of $7.72 million.

Institutional Trading of Metagenomi

Several hedge funds have recently made changes to their positions in the stock. JPMorgan Chase & Co. boosted its position in Metagenomi by 811.6% during the 4th quarter. JPMorgan Chase & Co. now owns 73,031 shares of the company's stock valued at $264,000 after purchasing an additional 65,020 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Metagenomi by 73.8% during the fourth quarter. Geode Capital Management LLC now owns 587,421 shares of the company's stock valued at $2,121,000 after acquiring an additional 249,390 shares during the period. Wells Fargo & Company MN grew its position in shares of Metagenomi by 54.5% during the fourth quarter. Wells Fargo & Company MN now owns 95,188 shares of the company's stock worth $344,000 after acquiring an additional 33,582 shares during the last quarter. Barclays PLC grew its position in shares of Metagenomi by 388.4% during the fourth quarter. Barclays PLC now owns 42,481 shares of the company's stock worth $153,000 after acquiring an additional 33,783 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD acquired a new stake in shares of Metagenomi in the 4th quarter worth about $39,000.

About Metagenomi

Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.